Osimertinib, a third-generation EGFR TKI that irreversibly inhibits EGFR-T790M mutations, is the preferred therapeutic option for EGFR-mutant NSCLC [6, 7]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.